TY - JOUR
T1 - Anti-inflammatory Effect of Cannabidiol and Palmitoylethanolamide Containing Topical Formulation on Skin in a 12-O-Tetradecanoylphorbol-13-Acetate-Induced Dermatitis Model in Mice
AU - Rundle, Chandler W.
AU - Rietcheck, Hope R.
AU - Maghfour, Jalal
AU - Dercon, Sam
AU - Fernandez, Jon
AU - Lio, Peter
AU - Dellavalle, Robert P.
AU - Fujita, Mayumi
AU - Yardley, Helena
N1 - Publisher Copyright:
© Lippincott Williams & Wilkins.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Background Chronic inflammatory skin disorders, such as atopic dermatitis, have significant disease burden worldwide. Although efficacious, the adverse effect profile of topical corticosteroids limits long-term use. As an alternative, cannabinoids have been shown to have anti-inflammatory therapeutic effects. Objective The aim of this study was to assess the effects of a topical cannabinoid product using dermatitis mouse model. Methods Thirty-five mice were randomized into treatment groups. 12-O-tetradecanoylphorbol-13-acetate was used as an irritant on 1 ear with the contralateral ear serving as a control. Ear edema was calipered. The test product containing 0.9% cannabidiol and palmitoylethanolamide was compared with a potent topical corticosteroid. Results Treatment with topical cannabinoid formulation reduced ear edema by 51.27% at 24 hours' and 65.69% at 48 hours' postapplication. Alternatively, mometasone reduced ear edema by 89.82% at 24 hours and 98.25% at 48 hours. Natural reduction (control) in ear edema was 26.32% at 24 hours and 44.21% at 48 hours. Both test groups resulted in significantly decreased edema when compared with baseline (P < 0.05), as well as compared with the negative control group (P < 0.05). Conclusions Significant reduction in ear edema, a marker for localized cutaneous inflammation, could be attributed to anti-inflammatory properties of cannabinoids. Although effects were less robust than topical corticosteroid use, cannabinoid formulations have therapeutic promise for dermatitis.
AB - Background Chronic inflammatory skin disorders, such as atopic dermatitis, have significant disease burden worldwide. Although efficacious, the adverse effect profile of topical corticosteroids limits long-term use. As an alternative, cannabinoids have been shown to have anti-inflammatory therapeutic effects. Objective The aim of this study was to assess the effects of a topical cannabinoid product using dermatitis mouse model. Methods Thirty-five mice were randomized into treatment groups. 12-O-tetradecanoylphorbol-13-acetate was used as an irritant on 1 ear with the contralateral ear serving as a control. Ear edema was calipered. The test product containing 0.9% cannabidiol and palmitoylethanolamide was compared with a potent topical corticosteroid. Results Treatment with topical cannabinoid formulation reduced ear edema by 51.27% at 24 hours' and 65.69% at 48 hours' postapplication. Alternatively, mometasone reduced ear edema by 89.82% at 24 hours and 98.25% at 48 hours. Natural reduction (control) in ear edema was 26.32% at 24 hours and 44.21% at 48 hours. Both test groups resulted in significantly decreased edema when compared with baseline (P < 0.05), as well as compared with the negative control group (P < 0.05). Conclusions Significant reduction in ear edema, a marker for localized cutaneous inflammation, could be attributed to anti-inflammatory properties of cannabinoids. Although effects were less robust than topical corticosteroid use, cannabinoid formulations have therapeutic promise for dermatitis.
KW - 12- O -tetradecanoylphorbol-13-acetate (TPA)
KW - ABBREVIATIONS
KW - atopic dermatitis (AD)
KW - cannabidiol (CBD)
KW - endogenous cannabinoid system (ECS)
KW - palmitoylethanolamide (PEA)
UR - http://www.scopus.com/inward/record.url?scp=85107864670&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107864670&partnerID=8YFLogxK
U2 - 10.1097/DER.0000000000000722
DO - 10.1097/DER.0000000000000722
M3 - Article
C2 - 33654018
AN - SCOPUS:85107864670
SN - 1710-3568
VL - 33
SP - 277
EP - 281
JO - Dermatitis
JF - Dermatitis
IS - 4
ER -